Clinical Trials Logo

Carcinoma, Hepatocellular clinical trials

View clinical trials related to Carcinoma, Hepatocellular.

Filter by:

NCT ID: NCT00492752 Completed - Clinical trials for Carcinoma, Hepatocellular

A Randomized, Double-Blinded, Placebo-Controlled Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma

Start date: October 2005
Phase: Phase 3
Study type: Interventional

The purpose of the study is - Find out if patients receiving Sorafenib will live longer - Find out if Sorafenib has any effect on patient reported outcomes - Find out if Sorafenib prevents the growth or shrinks liver tumors and / or their metastases - Determine the pharmacokinetics (PK) in patients with liver cancer

NCT ID: NCT00490685 Completed - Clinical trials for Carcinoma, Hepatocellular

Dose Escalation of Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)

Start date: April 2007
Phase: Phase 2
Study type: Interventional

The aim of the study is to evaluate, after radiological progression, efficacy in patients treated with Sorafenib at a dose of 600 mg bid compared to that in patients treated with best supportive care. Primary efficacy objective is progression free survival from randomization.

NCT ID: NCT00484211 Completed - Clinical trials for Hepatocellular Carcinoma

Study of NGR-hTNF as Single Agent in Patients Affected by Advanced or Metastatic Hepatocellular Carcinoma (HCC)

Start date: December 2006
Phase: Phase 2
Study type: Interventional

The main objective of the trial is to document the progression free survival (PFS) in advanced or metastatic hepatocellular carcinoma patients treated with NGR-hTNF as single agent. Safety will be established by clinical and laboratory assessment according to NCI-CTC criteria

NCT ID: NCT00483405 Completed - Liver Cancer Clinical Trials

Oxaliplatin, Capecitabine, and Cetuximab in Treating Patients With Advanced Liver Cancer

NRR
Start date: October 2006
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy, such as oxaliplatin and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Giving chemotherapy together with a monoclonal antibody may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving oxaliplatin and capecitabine together with cetuximab works in treating patients with advanced liver cancer.

NCT ID: NCT00482365 Completed - Liver Cancer Clinical Trials

National Registry and Blood Bank of Patients With Liver Cancer

Start date: April 2002
Phase: N/A
Study type: Observational

RATIONALE: Gathering health information about patients with liver cancer over time may help doctors learn more about the disease and may help the study of cancer in the future. PURPOSE: This clinical trial is developing a national registry and blood bank of patients with liver cancer.

NCT ID: NCT00479050 Completed - Clinical trials for Hepatocellular Carcinoma

Combination Chemoembolization and Radiofrequency Ablation for Hepatocellular Carcinoma Greater Than 3 cm

TACE-RFA
Start date: January 2001
Phase: Phase 1
Study type: Interventional

Combined the chemoembolization and Radiofrequency ablation for the hepatocellular carcinoma greater than 3 cm,the ablation volume of coagulation necrosis can be significantly increased,which may be enable effective treatment of patients with HCC greater than 3 cm.

NCT ID: NCT00478374 Completed - Clinical trials for Hepatocellular Carcinoma

Sorafenib With TACE to Treat Hepatocellular Carcinoma

S-TACE
Start date: May 2007
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the feasibility to combine sorafenib with transarterial chemoembolisation in patients suffering from hepatocellular carcinoma.The hypothesis is that sorafenib may prevent the development and growth of tumoral lesions not treated by chemoembolisation.

NCT ID: NCT00471965 Completed - Clinical trials for Carcinoma, Hepatocellular

Oxaliplatin + 5-FluoroUracil/LeucoVorin (5-FU/LV) (FOLFOX4) Versus Doxorubicin as Palliative Chemotherapy in Advanced Hepatocellular Carcinoma Patients

EACH
Start date: March 2007
Phase: Phase 3
Study type: Interventional

Primary: - Overall Survival (OS) Secondary: - Time to Tumor Progression (TTP) - Response Rate (RR) - Improvement of Quality of Life (QoL) - Safety - Secondary resection rate

NCT ID: NCT00467974 Completed - Clinical trials for Hepatocellular Carcinoma

Transarterial Ethanol Ablation (TEA) Versus Transcatheter Arterial Chemoembolisation (TACE) for Hepatocellular Carcinoma

Start date: June 2007
Phase: Phase 3
Study type: Interventional

The current randomized controlled trial comparing LEM and TACE aims to evaluate the safety and efficacy of LEM as compared to TACE for treating patients with unresectable HCC.

NCT ID: NCT00467194 Completed - Liver Cancer Clinical Trials

Sirolimus and Bevacizumab in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery

Start date: December 2006
Phase: Phase 1
Study type: Interventional

RATIONALE: Sirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab and sirolimus may also stop the growth of liver cancer by blocking blood flow to the tumor. Giving sirolimus together with bevacizumab may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of sirolimus when given together with bevacizumab in treating patients with liver cancer that cannot be removed by surgery.